In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 26, No. 9 ( 2008-03-20), p. 1489-1495
Abstract:
To evaluate and compare diagnostic sensitivity of positron emission tomography (PET) scanning in carcinoid and islet cell tumor patients with a serotonin and a catecholamine precursor as tracers. Patients and Methods Carcinoid (n = 24) or pancreatic islet cell tumor (n = 23) patients with at least one lesion on conventional imaging including somatostatin receptor scintigraphy (SRS) and computed tomography (CT) scan underwent 11 C-5-hydroxytryptophan ( 11 C-5-HTP) PET and 6-[F-18]fluoro-L-dihydroxy-phenylalanin ( 18 F-DOPA) PET. PET findings were compared with a composite reference standard derived from all available imaging along with clinical and cytologic/histologic information. Results In carcinoid tumor patients, per-patient analysis showed sensitivities for 11 C-5-HTP PET, 18 F-DOPA PET, SRS, and CT of 100%, 96%, 86%, 96%, respectively, and in islet cell tumors of 100%, 89%, 78%, 87%, respectively. In carcinoid patients, per-lesion analysis revealed sensitivities for 11 C-5-HTP PET, 11 C-5-HTP PET/CT, 18 F-DOPA PET, 18 F-DOPA PET/CT, SRS, SRS/CT, and CT alone of, respectively, 78%, 89%, 87%, 98%, 49%, 73%, and 63% and in islet cell tumors of 67%, 96%, 41%, 80%, 46%, 77%, and 68%, respectively. In all carcinoid patients 18 F-DOPA PET and 11 C-5-HTP PET detected more lesions than SRS (P 〈 .001). 11 C-5-HTP PET was superior to 18 F-DOPA PET in islet cell tumors (P 〈 .0001). In all cases, CT improved the sensitivity of the nuclear scans. Conclusion 18 F-DOPA PET/CT is the optimal imaging modality for staging in carcinoid patients and 11 C-5-HTP PET/CT in islet cell tumor patients.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2007.15.1126
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2008
detail.hit.zdb_id:
2005181-5
Bookmarklink